| Item Type | Name |
|
Academic Article
|
Selective serotonin reuptake inhibitors and delusional depression.
|
|
Academic Article
|
Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness.
|
|
Academic Article
|
Polysomnographic characteristics of young manic patients. Comparison with unipolar depressed patients and normal control subjects.
|
|
Academic Article
|
Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?
|
|
Academic Article
|
Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study.
|
|
Academic Article
|
An open label trial of C-1073 (mifepristone) for psychotic major depression.
|
|
Academic Article
|
How long should patients with psychotic depression stay on the antipsychotic medication?
|
|
Academic Article
|
Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression.
|
|
Academic Article
|
Olanzapine response in psychotic depression.
|
|
Academic Article
|
Placebo response in psychotic depression.
|
|
Academic Article
|
Olanzapine and haloperidol in first episode psychosis: two-year data.
|
|
Academic Article
|
A delusion assessment scale for psychotic major depression: Reliability, validity, and utility.
|
|
Academic Article
|
Depression secondary to anxiety: findings from the McLean Hospital Depression Research Facility.
|
|
Academic Article
|
Does major depressive disorder with somatic delusions constitute a distinct subtype of major depressive disorder with psychotic features?
|
|
Academic Article
|
The Rothschild Scale for Antidepressant Tachyphylaxis: reliability and validity.
|
|
Academic Article
|
Correlates of suicidality among patients with psychotic depression.
|
|
Academic Article
|
Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic.
|
|
Academic Article
|
Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.
|
|
Academic Article
|
Abnormal results of dexamethasone suppression tests in nondepressed patients with diabetes mellitus.
|
|
Academic Article
|
Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.
|
|
Academic Article
|
Correlation between patient and clinician assessments of depression severity in the PREVENT study.
|
|
Academic Article
|
Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder.
|
|
Academic Article
|
Relationships between multiple sclerosis and depression.
|
|
Academic Article
|
Psychotic and nonpsychotic depressions: I. Comparison of plasma catecholamines and cortisol measures.
|
|
Academic Article
|
Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday.
|
|
Concept
|
Psychiatric Status Rating Scales
|
|
Concept
|
Wechsler Scales
|
|
Academic Article
|
A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.
|
|
Academic Article
|
Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account.
|
|
Academic Article
|
Measuring psychotic depression.
|
|
Academic Article
|
Clinical and psychometric validation of the psychotic depression assessment scale.
|
|
Academic Article
|
Impaired insight into delusions predicts treatment outcome during a randomized controlled trial for Psychotic Depression (STOP-PD study).
|
|
Academic Article
|
Rating scales measuring the severity of psychotic depression.
|
|
Academic Article
|
Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS).
|
|
Academic Article
|
Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression.
|
|
Academic Article
|
Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis.
|
|
Academic Article
|
Changes in Depression Subtypes Among Men in STAR*D: A Latent Transition Analysis.
|
|
Academic Article
|
The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression.
|
|
Academic Article
|
Trial of SAGE-217 in Patients with Major Depressive Disorder.
|
|
Academic Article
|
Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial.
|
|
Academic Article
|
Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression.
|
|
Concept
|
Patient Reported Outcome Measures
|
|
Academic Article
|
Factor analysis of the CORE measure of psychomotor disturbance in psychotic depression: Findings from the STOP-PD II study.
|
|
Academic Article
|
Predictors of attrition during acute pharmacotherapy of psychotic depression in a clinical trial.
|